CSIMarket
 
Teva Pharmaceutical Industries Limited  (NYSE: TEVA)
Other Ticker:  
 
 
Price: $16.5500 $-0.23 -1.371%
Day's High: $16.88 Week Perf: -1.9 %
Day's Low: $ 16.39 30 Day Perf: 18.21 %
Volume (M): 12,526 52 Wk High: $ 22.80
Volume (M$): $ 207,299 52 Wk Avg: $17.41
Open: $16.68 52 Wk Low: $12.47



 Market Capitalization (Millions $) 19,181
 Shares Outstanding (Millions) 1,159
 Employees 37,851
 Revenues (TTM) (Millions $) 16,617
 Net Income (TTM) (Millions $) -1,320
 Cash Flow (TTM) (Millions $) -1,293
 Capital Exp. (TTM) (Millions $) 501

Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that specializes in the development, manufacture, and distribution of generic drugs, specialty medicines, and active pharmaceutical ingredients. The company was founded in Jerusalem, Israel in 1901, and has since grown to become one of the largest pharmaceutical companies in the world, with operations in more than 60 countries.

Teva's portfolio of products includes a wide range of generic and branded drugs, including medications for chronic and acute conditions, injectable drugs, biosimilars, and over-the-counter medicines. The company's size and scale allow it to offer affordable medications for a diverse range of conditions, helping to ensure that patients have access to the treatments they need.

In addition to its core business of manufacturing and distributing pharmaceuticals, Teva is also involved in drug development and research. The company has an R&D team dedicated to developing new drugs and technologies, with a particular focus on therapeutic areas such as central nervous system disorders, respiratory diseases, and oncology.

Teva is committed to environmental sustainability and ethical business practices. The company has implemented various programs to reduce its environmental impact, such as reducing water and energy use, and minimizing waste. Teva is also dedicated to promoting patient safety and ethical conduct, and has established strong compliance and ethics programs to ensure that all employees act with integrity and adhere to the highest ethical standards.

Teva employs more than 42,000 people worldwide and has a revenue of over $16 billion. The company is headquartered in Petah Tikva, Israel and operates manufacturing facilities all over the world, including in the United States, Europe, and Asia. Teva has an extensive global distribution network, allowing it to reach patients in nearly every corner of the world.


   Company Address: 124 Dvora HaNevi?a St. Tel Aviv 6944020
   Company Phone Number: 914-8213   Stock Exchange / Ticker: NYSE TEVA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV        0.07% 
ABT   -0.22%    
BMY        2.6% 
JNJ        2.39% 
MRK        2.91% 
PFE        1.95% 
• View Complete Report
   



Clinical Study

Unveiling Duvakitug?s Promise Teva and Sanofi Showcase Compelling Phase 2b Data at ECCO 2025

Published Sun, Feb 23 2025 10:31 AM UTC

: Recent developments in the pharmaceutical landscape concerning autoimmune diseases like Ulcerative Colitis (UC) and Crohn?s Disease (CD) have spotlighted Duvakitug an innovative anti-TL1A monoclonal antibody co-developed by Teva Pharmaceuticals and Sanofi. The new Phase 2b study results presented at the European Crohn?s and Colitis Organisation (ECCO) 2025 conference dem...

Stock Market Announcement

Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan

Published Thu, Dec 5 2024 11:00 PM UTC

Teva Pharmaceuticals? Strategic Shift: A New Chapter with JKI and Its Implications for ShareholdersIn a pivotal move on December 5, 2024, Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced a definitive agreement to transfer all shares of Teva Takeda Pharma Limited and its wholly-owned subsidiary, Teva Takeda Yakuhin Ltd. to JKI, an entity established by the...

Partnership

Teva and mAbxience Forge Ahead New Collaborative Agreement to Develop Anti PD-1 Biosimilar Transforms Oncology Land...

Published Thu, Oct 3 2024 12:30 PM UTC

In a significant move that underscores the ever-evolving landscape of cancer treatment, Teva Pharmaceuticals International GmbH and mAbxience have announced an expanded strategic partnership with a new global licensing agreement aimed at developing an innovative anti PD-1 oncology biosimilar candidate. This exciting collaboration builds upon the companies? initial partnershi...

Product Service News

Teva Pharmaceuticals Launches Generic Version of Sandostatin LAR Depot in the U.S.,

Published Tue, Oct 1 2024 12:29 PM UTC

Teva Pharmaceuticals Launches Generic Version of Sandostatin LAR Depot in the U.S. PARSIPPANY, N.J., Oct. 1, 2024 Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., has announced the launch of the first and only generic version of Sandostatin LAR Depot (octreotide acetate for injectable suspension) in the United States. This development marks a ...

Clinical Study

Long-Term Efficacy of Deutetrabenazine Demonstrated in European Patients with Tardive Dyskinesia

Published Mon, Sep 23 2024 5:00 AM UTC

News Tel Aviv, Israel, September 23, 2024 Teva Pharmaceutical Industries Ltd. announced promising results from a recent analysis at the European College of Neuropsychopharmacology (ECNP) annual congress in Milan, revealing that the treatment with deutetrabenazine has shown long-term efficacy in alleviating symptoms of Tardive Dyskinesia (TD) in European patients. This f...







Teva Pharmaceutical Industries Limited's Segments
Sale of Goods    87.25 % of total Revenue
Licensing Arrangements    0.93 % of total Revenue
Distribution    9.87 % of total Revenue
Other    0.77 % of total Revenue
International Markets    14.96 % of total Revenue
International Markets Sale of Goods    14.21 % of total Revenue
International Markets Licensing Arrangements    0.15 % of total Revenue
International Markets Distribution    0.28 % of total Revenue
International Markets Other    0.31 % of total Revenue
Other activities    5.29 % of total Revenue
Other activities Sale of Goods    3.32 % of total Revenue
Other activities Licensing Arrangements    0.03 % of total Revenue
Other activities Other    1.95 % of total Revenue
United States    49.09 % of total Revenue
United States Sale of Goods    38.91 % of total Revenue
United States Licensing Arrangements    0.57 % of total Revenue
United States Distribution    9.59 % of total Revenue
United States Other    0.03 % of total Revenue
Europe    30.69 % of total Revenue
Europe Sale of Goods    30.79 % of total Revenue
Europe Licensing Arrangements    0.18 % of total Revenue
Europe Other    -0.31 % of total Revenue
Reserves Included in Accounts Receivable net    2.54 % of total Revenue
Rebates    32.13 % of total Revenue
Medicaid and other governmental allowances    5.63 % of total Revenue
Chargebacks    51.09 % of total Revenue
Returns    1.77 % of total Revenue
Total reserves included in sales reserves and allowances    91.39 % of total Revenue
Generic products including OTC and biosimilars United States    21.82 % of total Revenue
Generic products including OTC and biosimilars Europe    25.42 % of total Revenue
Generic products including OTC and biosimilars International Markets    12.03 % of total Revenue
AJOVY United States    1.36 % of total Revenue
AJOVY Europe    1.49 % of total Revenue
AJOVY International Markets    0.72 % of total Revenue
AUSTEDO United States    10.18 % of total Revenue
AUSTEDO International Markets    0.39 % of total Revenue
BENDEKA and TREANDA United States    0.93 % of total Revenue
COPAXONE United States    1.39 % of total Revenue
COPAXONE Europe    1.08 % of total Revenue
COPAXONE International Markets    0.26 % of total Revenue
UZEDY United States    1 % of total Revenue
Anda United States    9.59 % of total Revenue
Respiratory Product Europe    1.41 % of total Revenue
Other United States    2.8 % of total Revenue
Other Europe    1.29 % of total Revenue
Other International Markets    1.57 % of total Revenue

  Teva Pharmaceutical Industries Limited Outlook

On December 20 2024 the Teva Pharmaceutical Industries Limited provided following guidance

nnTeva Pharmaceutical Industries Limitednn is set to provide an update on its financial performance and expectations for the future in a significant conference call. The company has announced that it will release its financial results for the fourth quarter and the full year of 2024, alongside its financial outlook for 2025, on Wednesday, January 29, 2025, at 7:00 a.m. Eastern Time.

Investors and s alike are keenly awaiting this announcement, as the details regarding the financial guidance for 2025 will be disclosed during the event. While Teva has confirmed that it will offer insights into its future financial outlook, it has yet to provide any specific figures or projections. This lack of detailed...





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com